TY  - JOUR
AU  - Fonseca, F.C.
AU  - Uhlenbruck, S.
AU  - Nédélec, R.
AU  - Sebold, D.
AU  - Buchkremer, H. P.
TI  - Temperature and Bias Effects on Sputtered Ceria Diffusion Barriers for Solid  Oxide Fuel Cells
JO  - Journal of the Electrochemical Society
VL  - 157
SN  - 0013-4651
CY  - Pennington, NJ
PB  - Electrochemical Society
M1  - PreJuSER-12540
SP  - B1515 - B1519
PY  - 2010
N1  - F.C.F. is thankful for the Brazilian agencies FAPESP (2007/08686-8) and CNPq (306422/2007-7). Thanks also to F. Vondahlen for helping us with PVD depositions and W. Herzhof and K. Portulidou for sample supplying/cathode depositions.
AB  - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000281306900040
DO  - DOI:10.1149/1.3476296
UR  - https://juser.fz-juelich.de/record/12540
ER  -